Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966092 | 0.83 | DRD3 (0.57) | DRD3KCNA3SIGMAR1DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL27509013 | 0.82 | OPRM1 (0.50) | SIGMAR1OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL6964398 | 0.80 | ADRA1A (0.52) | DRD3KCNA3DRD2DRD4OPRK1 | |
| Acetic Acid SCHEMBL614395 | 0.80 | SIGMAR1 (0.72) | KCNA3SIGMAR1DRD2MEN1KMT2A | |
| SCHEMBL11871040 | 0.79 | KCNA3 (0.49) | DRD3KCNA3SIGMAR1DRD2DRD4 | |
| SCHEMBL14000424 | 0.79 | SMN1; SMN2 (0.54) | SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL3554958 | 0.76 | KCNA3 (0.60) | KCNA3SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL7289267 | 0.76 | SIGMAR1 (0.53) | SIGMAR1OPRM1MEN1KMT2AKCNH2 | |
| SCHEMBL905002 | 0.76 | DRD3 (0.57) | DRD3DRD2DRD4OPRM1OPRD1 | |
| SCHEMBL11861549 | 0.76 | DRD3 (0.52) | DRD3OPRM1OPRD1OPRK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343784-A1 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | H LUNDBECK AS (DK) | 2024-10-17 | — | — | US | claimed |
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-20240269066-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING XEROPHTHALMIA | PRECVISION BIOTECHNOLOGIES LTD. (CN) | 2024-08-15 | — | — | US | claimed |
| CN-117903635-A | Wire clamp with flame-retardant insulating layer | 国网浙江省电力有限公司开化县供电公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4353264-A1 | USE OF CYP450 INHIBITOR IN INHIBITING OR KILLING MITES AND TREATING DRY EYE SYNDROME | Precvision Biotechnologies Ltd. (CN) | 2024-04-17 | — | — | EP | claimed |
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2024-03-14 | — | — | US | claimed |
| CN-117561081-A | Application of CYP450 inhibitor in inhibiting or killing mites and treating xerophthalmia | 广州珍实视界生物医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2023-12-07 | — | — | US | claimed |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | DMK PHARMACEUTICALS CORPORATION (US) | 2023-10-10 | — | — | US | claimed |
| EP-2534478-A1 | METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN | Leider, Harry (US) | 2012-12-19 | — | — | EP | claimed |
| WO-2011099985-A1 | METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN | LEIDER HARRY (US) | 2011-08-18 | — | — | WO | claimed |
| US-20110195520-A1 | METHODS OF NORMALIZING MEASURED DRUG CONCENTRATIONS AND TESTING FOR NON-COMPLIANCE WITH A DRUG TREATMENT REGIMEN | AMERITOX, LTD. (US) | 2011-08-11 | — | — | US | claimed |
| WO-2026106908-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | NEUHYLL THERAPEUTICS INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12630614-B2 | Treatment of headache using anti-CGRP antibodies hereof | H. LUNDBECK A/S (DK) | 2026-05-19 | — | — | US | disclosed |
| WO-2008002971-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007101161-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | DRD3 55/4885KCNA3 275/4885SIGMAR1 15/4885 |
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, ADCY1, ADCYAP1R1 | DRD3 549/4885KCNA3 1486/4885SIGMAR1 196/4885 |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | DRD3 19/4885KCNA3 959/4885SIGMAR1 5/4885 |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | DRD3 19/4885KCNA3 930/4885SIGMAR1 5/4885 |
| US-12630614-B2 | Treatment of headache using anti-CGRP antibodies hereof | CALCB, CALCA, CALCRL | DRD3 834/4885KCNA3 734/4885SIGMAR1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.